Inventor
JONES DAVID S
US35 patents
⚠️ This page may combine multiple inventors who share the name “JONES DAVID S”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
JOLLA PHARMA
14 patentsUS5552391ASep 3, 1996
Chemically-defined non-polymeric valency platform molecules and conjugates thereof
JOLLA PHARMA160 citations98
US6207160B1Mar 27, 2001
aPL immunoreactive peptides, conjugates thereof and methods of treatment for aPL antibody-mediated pathologies
JOLLA PHARMA70 citations95
US5726329AMar 10, 1998
Modified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotides
JOLLA PHARMA53 citations95
US5606047AFeb 25, 1997
Chemically-defined non-polymeric valency platform molecules and conjugates thereof
JOLLA PHARMA65 citations95
US6060056AMay 9, 2000
Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule
JOLLA PHARMA58 citations94
US7351855B2Apr 1, 2008
Chemically defined non-polymeric valency platform molecules and conjugates thereof
JOLLA PHARMA24 citations92
US6951939B2Oct 4, 2005
Multivalent platform molecules comprising high molecular weight polyethylene oxide
JOLLA PHARMA18 citations92
US5874552AFeb 23, 1999
Modified phosphorous intermediates for providing functional groups on the 5' end of oligonucleotides
JOLLA PHARMA29 citations92
US5633395AMay 27, 1997
Chemically-defined non-polymeric valency platform molecules and conjugates thereof
JOLLA PHARMA33 citations92
US6410775B1Jun 25, 2002
APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
JOLLA PHARMA18 citations91
US6399578B1Jun 4, 2002
Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
JOLLA PHARMA21 citations91
US6858210B1Feb 22, 2005
Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
JOLLA PHARMA33 citations88
US6458953B1Oct 1, 2002
Valency platform molecules comprising carbamate linkages
JOLLA PHARMA16 citations84
US7115581B2Oct 3, 2006
Chemically-defined non-polymeric valency platform molecules and conjugates thereof
JOLLA PHARMA1 citations52
NEORX CORP
8 patentsUS5075099ADec 24, 1991
Metal radionuclide chelating compounds for improved chelation kinetics
NEORX CORP121 citations99
US4988496AJan 29, 1991
Metal radionuclide chelating compounds for improved chelation kinetics
NEORX CORP142 citations98
US5175257ADec 29, 1992
Radiolabeled proteins for diagnostic or therapeutic use
NEORX CORP29 citations92
US5112953AMay 12, 1992
Radiolabeled proteins for diagnostic or therapeutic use
NEORX CORP30 citations92
US4885153ADec 5, 1989
Radiohalogenated for proteins
NEORX CORP24 citations92
US5625075AApr 29, 1997
Metal radionuclide chelating compounds for improved chelation kinetics
NEORX CORP6 citations74
US4933470AJun 12, 1990
Method of synthesis of vicinal diamines
NEORX CORP10 citations74
US5436352AJul 25, 1995
Metal radionuclide chelating compounds for improved chelation kinetics
NEORX CORP4 citations63
EASTMAN KODAK CO
4 patentsUS7034916B2Apr 25, 2006
Scheduling between digital projection and film projection corresponding to a predetermined condition
EASTMAN KODAK CO22 citations89
US6812994B2Nov 2, 2004
Streamlined methods and systems for scheduling and handling digital cinema content in a multi-theatre environment
EASTMAN KODAK CO45 citations89
US7053927B2May 30, 2006
System for optimizing the display and rendering of digital images for digital mastering
EASTMAN KODAK CO32 citations88
US7236227B2Jun 26, 2007
System for management of both pre-show and feature presentation content within a theatre
EASTMAN KODAK CO14 citations77